Skip to content
DataLookout
Menu

NCT07699133

Effect of Controlled Hypotension on GFAP and Cognition in Rhinoplasty

StatusCompleted
PhaseNot specified
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 8 words Show 4 more changesShow less
    • Completed without a posted recruiting period
    • Primary completion date changed from estimate of Feb 28, 2027 to Sep 30, 2026
    • Study sites: 0 to 1
    • Secondary endpoints: details revised at 2 of 2 entries
  2. Study Status, Eligibilityv2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Change in Serum Glial Fibrillary Acidic Protein (GFAP) Level
Timeframe: Baseline (T0: Post-induction) and 24 hours postoperatively (T1).

Secondary (2)

Change in Montreal Cognitive Assessment (MoCA) Score
Duration of Target Hypotension

Arms and interventions

Controlled Hypotension Cohort

Patients undergoing elective rhinoplasty receiving standard intraoperative controlled hypotension (Target MAP: 50-65 mmHg) maintained with sevoflurane and remifentanil.

Procedures: Controlled Hypotension (Standard of Care)

Sites

1 site in 1 country

  • Kahramanmaras Sutcu Imam University HospitalKahramanmaraş, Turkey (Türkiye)